Therapeutic Target Details
| Target ID: | T02 |
| Target Name: | Sodium/glucose cotransporter 2 |
| Synonyms: | SGLT2; Low affinity sodium-glucose cotransporter; Na(+)/glucose cotransporter 2; Solute carrier family 5 member 2; SLC5A2 |
| GENE: | SLC5A2 |
| Action: | inhibitor |
| Class: | Transporter |
| UniProtKB ID: | P31639 |
| Entry Name: | SC5A2_HUMAN |
| Related Drugs: | Empagliflozin; Canagliflozin; Dapagliflozin |
| Mechanism: | Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are increasingly used antidiabetic drugs that increase urinary glucose excretion by inhibiting the reabsorption of glucose in the proximal tubule of the kidney. Inhibition of SGLT2 causes an additional 60 to 80 g of glucose per day to be excreted out of the body, which leads to caloric loss and weight reduction. There is a growing expectation that this mechanism of SGLT2i will assist in the improvement of NAFLD. |
| Reference (PMIDs): | 27531551; 21606218; 26380062 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D058 | Canagliflozin | Chemical drug | DB08907 | SGLT2 inhibitor | Improve insulin resistance | Under clinical trials | Details |
| D101 | Dapagliflozin | Chemical drug | DB06292 | SLC5A2 antagonist; SLC5A2 inhibitor | Antidiabetic drug | Under clinical trials | Details |
| D122 | Empagliflozin | Chemical drug | DB09038 | SLC5A2 inhibitor; SGLT-2 inhibitor | Improve insulin resistance | Under clinical trials | Details |
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A08856 | 31963648 | J Clin Med | Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. | Details |
| A10891 | 31137547 | Medicina (Kaunas) | Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease. | Details |
| A17056 | 28019064 | Hepatol Res | Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. | Details |